After the Flashes Fade: Managing Genitourinary Syndrome of Menopause

Vasomotor symptoms fade, but genitourinary syndrome of menopause (GSM) does not. An estimated 84% of postmenopausal women experience GSM within six years of menopause, yet roughly half receive no treatment and approximately 60% report their clinician has never raised the topic. Left untreated, GSM is chronic and progressive, driving recurrent UTIs, dyspareunia, urinary urgency, and meaningful declines in quality of life. Course Features: – 3 video lectures, – 1 patient case explored, – 1 downloadable resource. Content Covered: This concise microlearning series equips primary care clinicians to close the GSM care gap through three short, clinically focused videos: Video 1: The dual hormonal decline of estrogen and androgen that drives GSM pathophysiology. Video 2: Efficient screening in clinical practice across the three symptom domains: genital, sexual, and urological. Video 3: Shared decision-making and presumptive language to individualize treatment selection and support adherence. Each video runs approximately five to seven minutes and features practice-ready patient dialogue, a running case, and guidance on menopause and genitourinary health. On completion, learners will be better able to recognize GSM, screen all perimenopausal and postmenopausal patients, and apply a shared decision-making framework to select evidence-based therapy: lubricants and moisturizers, vaginal estrogen, vaginal prasterone, or oral ospemifene. This program has received an unrestricted educational grant or in-kind support from Lupin Pharma Canada.